New schemes

Next Generation Sequencing (NGS) for somatic tumours

Labquality is introducing a new product line for Next Generation Sequencing (NGS) for somatic tumours. We are inviting a limited number of laboratories to participate free of charge in a pilot study for this new scheme. The scheme is suitable for all NGS methods.

Register by 31 January 2026.

Phosphatidyl ethanol in blood (PEth)

West Nile Virus, antibodies

HPV-related head and neck cancer control

Bacterial vaginosis and vaginitis multiplex, nucleic acid detection

Gram stain, vaginal fluid

Erythropoietin and Thrombopoietin

Immunosuppressants

Biochemical indicators of vitamin B12 deficiency (HoloTC, MMA, Homocysteine)

Norovirus, antigen detection

Helicobacter pylori, nucleic acid detection

Maternal serum screening

Mycoplasma genitalium, drug resistance multiplex, nucleic acid detection

Pipette control

Salivary Cortisol

Chemokine CXCL13

Interferon Gamma Release Assay (IGRA) for Mycobacterium tuberculosis

Faecal Elastase

Fungal infections, nucleic acid detection

Mycobacterium tuberculosis, drug resistance, nucleic acid detection

ACTH and Cortisol

HSV1&2/VZV/T.pallidum, nucleic acid detection

EQA for next-generation sequencing methods

We are developing external quality assessments for NGS methods in microbiology. If you are interested, please contact us!

EQA Product Catalogue

Our external quality assessment service program includes more than 250 quality assessment schemes, covering all specialities of laboratory medicine. Furthermore, the program includes an extensive selection of services designed for medical laboratories and point-of-care testing sites.

Integrated EQA Service

Our integrated EQA service is a completely new approach to external quality assessment. New programs integrate pre- and post-analytical EQA schemes into traditional analytical EQA, providing support according to the ISO 15189
standard requirements.

doctor-performing-medical-research-lab (1)

New EQA Schemes

We actively follow the development of laboratory medicine as we want to produce clinically relevant EQA schemes to serve clinical laboratories and point-of-care sites. We regularly launch new pilot studies and aim to expand our EQA portfolio by 5-10 new EQA schemes each year.

Local Partners Create Additional Value

We have EQA partners and distributors in more than 40 countries in Europe, South America, Southeast Asia, and the Middle East. Partner organisations sell and localise the EQA service in their territory. All partners have expertise in EQA and laboratory medicine.

Digital External Quality Assessment Programs

Our digital EQA product line provides an
advanced approach to external quality
assessment. Digital EQA programs or
virtual EQA programs use digital images,
videos, virtual microscopy technology, and
questionnaires as EQA samples.

Try the Demo